Scientists sequenced the genome of 15 varieties of wheat

December 1, 2020
It’s December. Today, the wheat genome is making headlines. We dig in, plus get more insight from Dr. Michelle on why you can trust the safety and science of the COVID-19 vaccines. (690 words, 3 minutes, 25 seconds)
BIO

It’s December. Today, the wheat genome is making headlines. We dig in, plus get more insight from Dr. Michelle on why you can trust the safety and science of the COVID-19 vaccines. (690 words, 3 minutes, 25 seconds)

 

Scientists sequenced 15 varieties of wheat—here’s why it matters

 
 

Did you think about the genetic makeup of your toast this morning? No? Well, some researchers did—and what they've discovered could help feed the world.

A team of international researchers sequenced the genome of 15 varieties of wheat from around the world,reports Agri-Pulse. Researchers at Kansas State University worked with the 10+ Genome Project led by the University of Saskatchewan with support from the National Science Foundation, U.S. Department of Agriculture, and Kansas Wheat.

“The project’s goal is to characterize the wheat ‘pan genome,’ or all genes and genetic variation within a species,” which could advance “wheat discovery and breeding,” explains the report.

Read their findings in Nature.

This knowledge could feed the world—by helping scientists pinpoint the precise genes that lead to larger yields, for example, or reduce the gluten content to make wheat more tolerable and nutritious for everyone.

This isn’t a new idea. In 1970, scientist Norman Borlaug received a Nobel Peace Prize for his work to introduce “a single gene change in wheat to decrease the crop’s height,” which contributed to greater yield and thus increased the global food supply, explains Innovature.

But now, we have the tools to make these discoveries faster and more efficiently—like CRISPR, which makes small, precise changes to an organism’s own genome to “speed up the process of variation and, as a result, get us to higher quality crops faster,” says plant physiologist Dr. Amita Mohan.

So, what’s next? Clearly, we have the science to feed the growing population. Now, we need policy to catch up to ensure these innovations can get where they need to go.

Learn more about what BIO's doing to grow trust in innovation.

 
 
 
Twitter
 
LinkedIn
 
Facebook
 
 

Why you can trust the science and speed of the COVID-19 vaccines

 
 

The COVID-19 vaccines are speeding along—but will they be safe? BIO’s Dr. Michelle McMurry-Heath answered this question (and more) in a recent conversation with Dr. John Whyte, Chief Medical Officer at WebMD.

 
Dr. Michelle McMurry-Heath on WebMD Coronavirus in Context
 

It’s another good week for COVID-19 vaccine news. Yesterday, Moderna applied for emergency use authorization (EUA) of its candidate, which was found to be 94.1% effective—and 100% effective against severe disease. 

It’s one of more than 800 R&D programs targeting COVID-19 that have been launched since the start of the pandemic, including 191 vaccines—and two (Moderna and Pfizer/BioNTech) are already under review by the U.S. Food and Drug Administration (FDA).

That was fast. Yesthanks in part to “collaborations like we’ve never known before” between companies of all sizes and government, explained Dr. Michelle.

But you can trust the science. “This is not just new developments that were starting at ground zero,” she said. “We really saw years of scientific advances being applied to the pandemic.”

The scientists and regulators “have not wavered in the face of political pressure or even in the face of public concern or demand,” she continued. “They’re really just trying to let the science speak for itself.”

So, when will the vaccine be available to the general public?Watch to get her prediction. 

They also discussed the importance of diversity in clinical trials—which we’re seeing in these vaccine candidates. Moderna’s trial was around 35% people of color, while Pfizer’s was around 40%—an important step towards ensuring the trials are representative of the patients hit hardest by this disease. Learn more about what we’re doing to improve diversity of clinical trials and the biotechnology industry.

 

More Health Care News:

Time: On World AIDS Day, those who fought the 1980s epidemic find striking differences and tragic parallels in COVID-19
“Many have pointed out the stark public response differences between the two outbreaks and how the lag in outcry over the deadliness of AIDS cost lives.” 

 
Twitter
 
LinkedIn
 
Facebook
 
 
Sanofi Uncut: Perspectives on Health Inequities
Addressing disparities in healthcare requires our collective efforts—open and transparent conversations, innovative thinking, a deep commitment to acknowledging the issues as well identifying and enacting solutions to address these challenges.

To elevate awareness and advance meaningful dialogue, Sanofi Genzyme is hosting a special online event, Uncut: Perspectives on Health Inequities,  featuring BIO President and CEO Dr. Michelle McMurry-Heath and Bill Sibold, EVP and Head of Sanofi Genzyme, President of Sanofi North America, and a member of BIO's Executive Committee.

Join the event live on LinkedIn TODAY, Tuesday, December 1, at 4:00 PM ET.


 
 
 
 
BIO Beltway Report
BIO Beltway Report
 
Paragraph (sm) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis sample link.
 

President Trump’s Tuesday: No public events scheduled. White House COVID-19 adviser Dr. Scott Atlas resigned

President-elect Biden’s Tuesday:POLITICO takes a look at how Biden’s chief of staff Ron Klain, who oversaw the Ebola response under President Obama, will tackle the coronavirus.

What’s Happening on Capitol Hill: All eyes will be on the CDC's Advisory Committee on Immunization Practices (ACIP) meeting, streaming live starting at 2 PM ET. Senate Banking will hold a hearing, The Quarterly CARES Act Report to Congress, with Treasury Secretary Steve Mnuchin and Federal Reserve Chair Jerome Powell. Meanwhile: “Bipartisan Senate group revives coronavirus relief talks,” reports POLITICO.

 
 
Paragraph (normal) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus sample link.
 
Twitter
 
LinkedIn
 
Facebook